United Therapeutics Corporation (UTHR)

Market Cap	18.25B
Revenue (ttm)	3.08B
Net Income (ttm)	1.24B
Shares Out	45.23M
EPS (ttm)	25.63
PE Ratio	15.74
Forward PE	14.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	551,369
Open	398.41
Previous Close	397.97
Day's Range	397.97 - 405.41
52-Week Range	266.98 - 436.95
Beta	0.62
Analysts	Strong Buy
Price Target	449.13 (+11.28%)
Earnings Date	Oct 29, 2025

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 17, 1999
• Employees: 1,305
• Stock Exchange: NASDAQ
• Ticker Symbol: UTHR
• Website: https://www.unither.com

Financial Performance

In 2024, United Therapeutics's revenue was $2.88 billion, an increase of 23.63% compared to the previous year's $2.33 billion. Earnings were $1.20 billion, an increase of 21.35%.

Analyst Summary

According to 15 analysts, the average rating for UTHR stock is "Strong Buy." The 12-month stock price target is $449.13, which is an increase of 11.28% from the latest price.

Price Target

$449.13

(11.28% upside)

Analyst Consensus: Strong Buy